SIM
RNAC icon

Spark Investment Management’s Cartesian Therapeutics RNAC Stock Holding History

Spark Investment Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-963
Closed -$69K – 225
2020
Q1 		$69K Buy
+963
New +$93K 0.04% 308

Other funds holding RNAC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Spark Investment Management's RNAC Position: Q2 2020 in Review

Spark Investment Management sold out of Cartesian Therapeutics (RNAC) in Q2 2020, closing a stake of 963 shares — an estimated $69K sold.

Spark Investment Management first reported a position in RNAC in Q1 2020 and held it in 1 quarter. The position peaked at $69K in Q1 2020. 81 funds tracked by Wall St. Rank hold RNAC as of Q2 2020.

  • Spark Investment Management reported no remaining Cartesian Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Spark Investment Management sold 963 Cartesian Therapeutics shares in Q2 2020, an estimated $69K.
  • Spark Investment Management first reported a position in Cartesian Therapeutics in Q1 2020 and held it in 1 quarter.
  • Spark Investment Management's Cartesian Therapeutics position peaked at $69K in Q1 2020.
  • 81 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.